Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Zanidatamab Combined With Chemotherapy in Operable HER2 Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma (GEA): A Phase 1b/2a Single-Arm Trial

NCT07477444 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT07477444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07477444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Zanidatamab Combined With Chemotherapy in Operable HER2 Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma (GEA): A Phase 1b/2a Single-Arm Trial
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
June 30, 2033
Enrollment
29 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal cancer